Clinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without
emtricitabine as antiretroviral pre-exposure prophylaxis (PrEP) can decrease the risk of …

Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years
where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling …

The antiretroviral drug combination emtricitabine and tenofovir disoproxil fumarate
(TDF/FTC) taken as pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection …

Oral HIV pre-exposure prophylaxis (PrEP) is a promising new biomedical prevention
approach in which HIV-negative individuals are provided with daily oral antiretroviral …

Background Mathematical transmission models are increasingly used to guide public health
interventions for infectious diseases, particularly in the context of emerging pathogens; …

Current population genotyping methods for resistance monitoring are high cost and low
throughput. NGS, combined with simpler sample collection and storage matrices (eg dried …

The benefit of preventing HIV-1 infections with TDF/FTC PrEP far outweighs the risk of drug-
resistant infection, provided PrEP is not started in persons with undiagnosed HIV-1 infection …

Abstract Pre-exposure prophylaxis (PrEP), the use of antiretrovirals (ARVs) by human
immunodeficiency virus (HIV)–uninfected individuals to prevent acquisition of the virus …

Objective To assess current and intended future use of pre-exposure prophylaxis (PrEP)
among men who have sex with men (MSM) and characterise those attending sexual health …

Background: Preexposure prophylaxis (PrEP) with tenofovir and emtricitabine can prevent
new HIV-1 infections, but there is a concern that use of PrEP could increase HIV drug …